REVANCE THERAPEUTICS INC's ticker is RVNC and the CUSIP is 761330109. A total of 113 filers reported holding REVANCE THERAPEUTICS INC in Q2 2018. The put-call ratio across all filers is 1.07 and the average weighting 0.7%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2019 | $1,075,000 | -16.9% | 82,862 | +0.9% | 0.00% | 0.0% |
Q1 2019 | $1,294,000 | -12.1% | 82,137 | +12.3% | 0.00% | -25.0% |
Q4 2018 | $1,472,000 | -24.3% | 73,137 | -6.6% | 0.00% | -20.0% |
Q3 2018 | $1,945,000 | -10.8% | 78,287 | -1.4% | 0.01% | -16.7% |
Q2 2018 | $2,180,000 | -11.5% | 79,417 | -0.7% | 0.01% | -14.3% |
Q1 2018 | $2,463,000 | -12.3% | 79,959 | +1.8% | 0.01% | -12.5% |
Q4 2017 | $2,809,000 | +72.9% | 78,560 | +33.2% | 0.01% | +60.0% |
Q3 2017 | $1,625,000 | +7.0% | 58,966 | +2.5% | 0.01% | 0.0% |
Q2 2017 | $1,518,000 | +32.8% | 57,516 | +4.6% | 0.01% | +25.0% |
Q1 2017 | $1,143,000 | -3.4% | 54,971 | -3.8% | 0.00% | 0.0% |
Q4 2016 | $1,183,000 | +30.9% | 57,171 | +2.6% | 0.00% | +33.3% |
Q3 2016 | $904,000 | +96.9% | 55,741 | +65.1% | 0.00% | +50.0% |
Q2 2016 | $459,000 | +28.2% | 33,761 | +64.4% | 0.00% | +100.0% |
Q1 2016 | $358,000 | 0.0% | 20,531 | +95.9% | 0.00% | 0.0% |
Q4 2015 | $358,000 | – | 10,481 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
NovaQuest Capital Management, L.L.C. | 1,558,426 | $42,779,000 | 61.17% |
Essex Woodlands Management, Inc. | 3,342,047 | $91,739,000 | 21.30% |
Sio Capital Management, LLC | 101,292 | $2,780,000 | 1.54% |
Fosun International Ltd | 472,532 | $12,971,000 | 0.66% |
Rhenman & Partners Asset Management AB | 203,181 | $5,577,000 | 0.57% |
ArrowMark Colorado Holdings LLC | 1,804,275 | $49,527,000 | 0.46% |
ESSEX INVESTMENT MANAGEMENT CO LLC | 87,355 | $2,398,000 | 0.30% |
FOX RUN MANAGEMENT, L.L.C. | 18,477 | $507,000 | 0.16% |
Phoenix Investment Adviser LLC | 2,400 | $66,000 | 0.12% |
Quinn Opportunity Partners LLC | 33,100 | $909,000 | 0.12% |